Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
9(60%)
Results Posted
300%(3 trials)

Phase Distribution

Ph phase_4
3
20%
Ph phase_3
3
20%
Ph phase_2
7
47%

Phase Distribution

0

Early Stage

7

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
7(53.8%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
3(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

9

trials recruiting

Total Trials

15

all time

Status Distribution
Active(11)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

Recruiting5
Active, not recruiting4
unknown2
Not yet recruiting2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
9
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 27 (53.8%)
Phase 33 (23.1%)
Phase 43 (23.1%)

Trials by Status

active_not_recruiting427%
completed17%
unknown213%
withdrawn17%
not_yet_recruiting213%
recruiting533%

Recent Activity

9 active trials
Showing 5 of 15
recruitingphase_2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT06570798
not_yet_recruitingphase_2

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

NCT07222553
recruitingphase_2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT06987539
not_yet_recruitingphase_4

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

NCT07010302
active_not_recruitingphase_3

Myasthenia Gravis Inebilizumab Trial

NCT04524273
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT06570798Phase 2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Recruiting
NCT07222553Phase 2

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

Not Yet Recruiting
NCT06987539Phase 2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Recruiting
NCT07010302Phase 4

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Not Yet Recruiting
NCT04524273Phase 3

Myasthenia Gravis Inebilizumab Trial

Active Not Recruiting
NCT04540497Phase 3

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

Active Not Recruiting
NCT05198557Phase 3

A Study of MT-0551 in Patients With Systemic Sclerosis

Active Not Recruiting
NCT05549258Phase 2

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Recruiting
NCT06180278Phase 4

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Active Not Recruiting
NCT04372615Phase 2

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Recruiting
NCT05891379

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

Recruiting
NCT04174677Phase 2

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

Withdrawn
NCT06212245Phase 4

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Unknown
NCT06068829

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

Unknown
NCT02200770Phase 2

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15